Find A Clinical Trial

Disease Type: Lung

Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location
Trial ID FURMO
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location
Trial ID VS-6766-204
Sponsor ID RAMP 204

A Phase 1/2 Study of VS-6766 in Combination with Adagrasib in Patients with KRAS G12C Mutant Non-Small Cell Lung Cancer

1 Location
Trial ID H002-101
Sponsor ID Hongyun Biotech

A Phase 1/2a, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-Tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-Small Lung Cancer

1 Location
Trial ID DZ2019E0001
Sponsor ID Dizal Jiangsu

A Phase 1/2, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

3 Locations
Trial ID 21498
Sponsor ID RAMP 203

A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)

1 Location
Trial ID 21239
Sponsor ID 61186372NSC3002

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

3 Locations
Trial ID 20388
Sponsor ID Codebreak 101, Subprotocol I

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)

1 Location
Trial ID 20386
Sponsor ID Codebreak 101, Subprotocol G

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)

1 Location
Trial ID Oncocyte PADMA
Sponsor ID Oncocyte

Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer (NSCLC) Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation

Principal Investigator
Sandeep J. Khandhar, MD, FACS
1 Location